Second Genome is a biopharmaceutical company with a mission to redefine disease in the context of microbiome medicine. We leverage our proprietary microbiome drug discovery and development platform to identify effective peptides, proteins and small molecule therapeutics that can address unmet medical needs.
Our lead program, SG-2-0776, is a novel therapeutic protein derived from the microbiome that promotes mucosal healing of damaged epithelial surfaces. SG-2-0776 is currently in pre-clinical and IND-enabling studies, and we plan to initiate clinical development in 2021.